FDA regulations ensure that each drug brought to market has shown safety and efficacy compared to a placebo or a comparison drug. FDA regulations do not require comparisons among multiple drugs to determine which drug works best. Pharmaceutical companies have financial incentives to show their own medications in the best light. Consequently, they have no incentive to spend millions of dollars on high quality, objective studies that could potentially reflect badly on their own product. It is no coincidence, therefore, that the CATIE study, which punctured the illusion that newer is necessarily better, was financed by the National Institute of Mental Health and not by private industry. Clearly independent sources of funding are needed to support high quality and impartial drug-to-drug comparisons.